SCHEMBL1371071

SCHEMBL1371071

O=C(c1cc2cc([N+](=O)[O-])cc(Br)c2sc1=O)c1cc2cc([N+](=O)[O-])cc(Br)c2sc1=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.37
CYP3A4 P08684 2/20 0.37
GLA P06280 1/20 0.36
MAOB P27338 2/20 0.35
MAOA P21397 1/20 0.35
NQO2 P16083 1/20 0.35
POLB P06746 1/20 0.35
CA12 O43570 1/20 0.35
CA9 Q16790 1/20 0.35
LMNA P02545 1/20 0.34
GPR35 Q9HC97 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
MAPT P10636 3/20 0.32
HTT P42858 2/20 0.32
CRHBP P24387 1/20 0.32
CRHR2 Q13324 1/20 0.32
ESPL1 Q14674 1/20 0.32
KDM4E B2RXH2 1/20 0.32
NPC1 O15118 1/20 0.32
PKM P14618 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1367177 0.84 ALDH1A1 (0.41) ALDH1A1CYP3A4MAOBMAOAPOLB
SCHEMBL1368968 0.80 MAPT (0.46) ALDH1A1MAOBLMNASMN1; SMN2MAPT
SCHEMBL31573253 0.77 GPR35 (0.40) ALDH1A1CYP3A4GLANQO2POLB
SCHEMBL1371069 0.77 MAOB (0.40) ALDH1A1MAOBMAOAPOLBCA12
SCHEMBL1369275 0.74 POLB (0.52) ALDH1A1CYP3A4MAOBMAOAPOLB
SCHEMBL1369287 0.73 ALDH1A1 (0.39) ALDH1A1MAOBMAOAPOLBLMNA
SCHEMBL1368732 0.71 ALDH1A1 (0.43) ALDH1A1CYP3A4GLAMAOBMAOA
SCHEMBL1368742 0.71 GPR35 (0.54) ALDH1A1MAOBMAOAPOLBCA12
SCHEMBL1368146 0.70 MEN1 (0.44) ALDH1A1CYP3A4MAOAPOLBCA12
SCHEMBL31573233 0.66 ALDH1A1 (0.43) ALDH1A1CYP3A4GLANQO2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275650-A1 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2009-11-05 US claimed
WO-2006132947-A2 3-ACYL COUMARINS, THIOCHROMONES AND QUINOLONES AND THERAPEUTIC USES THEREOF TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2006-12-14 WO claimed
US-8067461-B2 3-acyl coumarins, thiochromones and quinolones and therapeutic uses thereof TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2011-11-29 US disclosed
US-20090275650-A1 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2009-11-05 US disclosed
WO-2006132947-A2 3-ACYL COUMARINS, THIOCHROMONES AND QUINOLONES AND THERAPEUTIC USES THEREOF TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2006-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275650-A1 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof NQO2, NQO1, HCCS ALDH1A1 617/4885CYP3A4 233/4885GLA 1702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.